Video

Dr. Upadhyaya Discusses Drug Development for Pediatric Patients With Brain Tumors

Author(s):

Santhosh Upadhyaya, MD

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses drug development for pediatric patients with brain tumors.

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses drug development for pediatric patients with brain tumors.

Drug development is challenging, explains Upadhyaya, especially as it relates to pediatric patients with brain tumors because there is always a concern over blood-brain barrier penetration. In the 10-year-long SJYC07 trial presented at the 2018 ASCO Annual Meeting, results revealed that children with molecularly defined ependymoma and other malignant brain tumors under the age of 3 responded well to radiation therapy. Though the trial showed that children can be safely treated with radiation to improve outcomes, new drugs are needed.

Once a drug is developed and a trial is designed, collaboration is key, notes Upadhyaya. Physicians hope that through this collaboration, new medications will be discovered that target the pathways that are present in pediatric ependymomas.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
FDA
December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Lee-Kim on Fostering a Fulfilling Fellowship in Oncology
June 28th 2021

Lee-Kim on Fostering a Fulfilling Fellowship in Oncology

FDA
November 25th 2024

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia
October 29th 2024

FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia

FDA
October 16th 2024

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML